Cargando…
Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy
Cancer therapies can provide substantially improved survival in some patients while other seemingly similar patients receive little or no benefit. Strategies to identify patients likely to respond well to a given therapy could significantly improve health care outcomes by maximizing clinical benefit...
Autores principales: | Lucas, Julie L., Tacheny, Erin A., Ferris, Allison, Galusha, Michelle, Srivastava, Apurva K., Ganguly, Aniruddha, Williams, P. Mickey, Sachs, Michael C., Thurin, Magdalena, Tricoli, James V., Ricker, Winnie, Gildersleeve, Jeffrey C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542629/ https://www.ncbi.nlm.nih.gov/pubmed/28771597 http://dx.doi.org/10.1371/journal.pone.0182739 |
Ejemplares similares
-
Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy
por: Mandl, Stefanie J, et al.
Publicado: (2014) -
A Phase I Trial of Pox PSA vaccines (PROSTVAC(®)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer
por: DiPaola, RS, et al.
Publicado: (2006) -
A Depth-Dependent Integrated VF Simulation for Analysis and Visualization of Glaucomatous VF Defects
por: Liu, Ping, et al.
Publicado: (2020) -
Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report
por: Monge, Cecilia, et al.
Publicado: (2018) -
ALG: Automated Genotype Calling of Luminex Assays
por: Bourgey, Mathieu, et al.
Publicado: (2011)